Feb 28, 2023
Dr. Robert Risinger is the Chief Medical Officer for Neuroscience at BioXcel Therapeutics, identifying molecules that have off-target indications to address unmet neurological diseases. The initial focus is on acute agitation and the molecules that will address this agitation in patients with bipolar and schizophrenia. ...
Feb 28, 2023
Dr. Robert Risinger is the Chief Medical Officer for Neuroscience at BioXcel Therapeutics, identifying molecules that have off-target indications to address unmet neurological diseases. The initial focus is on acute agitation and the molecules that will address this agitation in patients with bipolar and schizophrenia. ...
Feb 27, 2023
Neal Koller is the CEO of Alphyn Biologics, which focuses on improving therapy for skin diseases. Their first topical drug treats both atopic dermatitis and atopic dermatitis with secondary infection. The goal is to treat the recognized immune component of the disease and the bacterial component. Those most affected...
Feb 27, 2023
Neal Koller is the CEO of Alphyn Biologics, which focuses on improving therapy for skin diseases. Their first topical drug treats both atopic dermatitis and atopic dermatitis with secondary infection. The goal is to treat the recognized immune component of the disease and the bacterial component. Those most affected...
Feb 24, 2023
Brett Furst, President of HHS Technology Group, is carrying on the mission of efforts started at the beginning of the COVID outbreak to collaboratively share data to provide insights to those doing research, drug development, and addressing the impact of the pandemic on vulnerable populations. Maintaining this...